Axil Capital is a venture capitalventure capital and private equity firm investing in early-stage biomedical & healthcare technology companies that is headquartered in Tokyo, Japan and was founded in 2017 by Fred Shane and Hiroshi Gonaikawa. Axil Capital was spun out of Mizuho Securities in 2017 after receiving investment from the Japanese Government, a global pharmaceutical company, and a few small investors.